# US 2026/0077076 A1 · Agents for cleaving labels from biomolecules in vivo

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077076 A1
- Document ID: US20260077076A1
- Status: Published application
- Kind: A1
- Application number: 19/400,602
- Filed: 2025-11-25
- Published: 2026-03-19
- Earliest claimed: 2019-06-17
- Assignees: Tagworks Pharmaceuticals B.V.
- Applicants: Tagworks Pharmaceuticals B.V.
- Inventors: Raffaella ROSSIN; Marc Stefan ROBILLARD; Laurens Henri Johan KLEIJN
- Web page: https://patentgrep.com/patent/US20260077076A1

## CPC

- A61K 51/1051: {the tumor cell being from breast, e.g. the antibody being herceptin}
- C07K 16/32: against translation products of oncogenes
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61P 35/02: specific for leukemia
- C07D 229/00: Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms
- C07K 2317/77: Internalization into the cell
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed herein are compounds, combinations, and kits that can be used to more quickly remove radionuclides from a subject, preferably a human being. Said compounds, combinations and kits can also be used to increase the tumor-to-blood ratio, or to more rapidly and/or conveniently achieve such an increase, of a label in targeted imaging or targeted radiotherapy in a subject, preferably a human being.

## Claims

### Claim at position 1

-14. (canceled)

### Claim 15

A method comprising administering a compound of Formula (1) to a subject and subsequently administering to said subject a diene; wherein said compound of Formula (1) is:
and pharmaceutically acceptable salts thereof, wherein
the compound of Formula (1) comprises at least one Label and at least one Administration Agent;
the Label is a moiety comprising a radionuclide;
the Administration Agent is an antibody, an antibody fragment which is at least a portion of the variable region of the immunoglobulin that binds to its target, or an antibody mimetic;
each X1, X2, X3, X4 is independently selected from the group consisting of
—C(R47)2—, —NR37—, —C(O)—, —O—, such that at most two of X1, X2, X3, X4 are not
—C(R47)2—, and with the proviso that no sets consisting of adjacent atoms are present selected from the group consisting of —O—O—, —O—N—, —C(O)—O—, N—N—, and —C(O)—C(O)—;
X5 is —C(R47)2— or —CHR48;
each R48 is independently selected from the group consisting of -LB, and -LA;
R48 is bound to the remainder of the compound of Formula (1) via a part of R48 that is —O—, —S—, —OC(O)—, —OC(S)—, —SC(O)—, or —SC(S)—;
LB is a moiety satisfying Formula (2):
Formula (2); wherein
the dashed line denotes a bond to the remainder of the compound of Formula (1); SL is a linker, which optionally is a self-immolative linker LC;
each R98 individually is the Label or a clearance-directing group, wherein a clearance-directing group is a moiety that directs a compound to an excretory organ;
each d independently is 0 or 1;
e is an integer in a range of from 0 to 4; LA is a moiety satisfying Formula (3):
Formula (3); wherein
the dashed line denotes a bond to the remainder of the compound of Formula (1); each s is independently 0 or 1;
i is an integer in a range of from 0 to 4;
each SP independently is a spacer, which optionally is a self-immolative linker LC; AA denotes the Administration Agent;
CC denotes a Construct-C, wherein each Construct-C is independently selected from the group consisting of the Label and the Administration Agent;
provided that LA only comprises both the Label and the Administration Agent when LA is R48;
provided that if LA being R48 comprises both the Label and the Administration Agent, then the SP linked to said Label and said Administration Agent is a self-immolative linker, wherein said Label and said Administration Agent will be uncoupled after reaction of the compound of Formula (1) with a Cleaving Agent due to the self-immolative character of the linker, wherein the Cleaving Agent is a diene;
each R47 is independently selected from the group consisting of
hydrogen, -LB, -LA, —(SP)i—CC, —F, —Cl, —Br, —I, —OR37, —N(R37)2, —SO3, —PO3—, —NO2, —CF3, —SR37, S(═O)2N(R37)2, OC(═O)R37, SC(═O) R37, OC(═S)R37, SC(═S)R37, NR37C(═O)—R37, NR37C(═S)—R37, NR37C(═O)O—R37, NR37C(═S)O—R37, NR37C(═O)S—R37, NR37C(═S)S—R37, OC(═O)N(R37)2, SC(═O)N(R37)2, OC(═S)N(R37)2, SC(═S)N(R37)2, NR37C(═O)N(R37)2, NR37C(═S)N(R37)2, C(═O)R37, C(═S)R37, C(═O)N(R37)2, C(═S)N(R37)2, C(═O)O—R37, C(═O)S—R37, C(═S)O—R37, C(═S)S—R37, S(O)R37, —S(O)2R37, NR37S(O)2R37, —ON(R37)2, —NR37OR37, C1-C24 alkyl groups, C2-C24 alkenyl groups, C2-C24 alkynyl groups, C6-C24 aryl groups, C2-C24 heteroaryl groups, C3-C24 cycloalkyl groups, C5-C24 cycloalkenyl groups, C12-C24 cycloalkynyl groups, C3-C24 (cyclo)alkyl(hetero)aryl groups, C3-C24 (hetero)aryl(cyclo)alkyl, C4-C24 (cyclo)alkenyl(hetero)aryl groups, C4-C24 (hetero)aryl(cyclo)alkenyl groups, C4-C24 (cyclo)alkynyl(hetero)aryl groups, C4-C24 (hetero)aryl(cyclo)alkynyl groups, C4-C24 alkylcycloalkyl groups, and C4-C24 cycloalkylalkyl groups; wherein i is an integer in a range of from 0 to 4,
wherein the alkyl groups, alkenyl groups, alkynyl groups, aryl, heteroaryl, cycloalkyl groups, cycloalkenyl groups, cycloalkynyl groups, (cyclo)alkyl(hetero)aryl groups, (hetero)aryl(cyclo)alkyl groups, (cyclo)alkenyl(hetero)aryl groups, (hetero)aryl(cyclo)alkenyl groups, (cyclo)alkynyl(hetero)aryl groups, (hetero)aryl(cyclo)alkynyl groups, alkylcycloalkyl groups, cycloalkylalkyl groups are optionally substituted with a moiety selected from the group consisting of —Cl, —F, —Br, —I, —OR37, —N(R37)2, —SO3R37, —PO3(R37)2, —PO4(R37)2, —NO2, —CF3, ═O, ═NR37, and —SR37, and optionally contain one or more heteroatoms selected from the group consisting of O, S, NR37, P, and Si, wherein the N, S, and P atoms are optionally oxidized, wherein the N atoms are optionally quaternized;
two R47 and/or R37 are optionally comprised in a ring,
two R47 and/or R37 are optionally comprised in a ring so as to form a ring fused to the eight membered trans-ring of Formula (1);
each R37 is independently selected from the group consisting of hydrogen, -LB, -LA, —(SP)i—CC, C1-C24 alkyl groups, C2-C24 alkenyl groups, C2-C24 alkynyl groups, C6-C24 aryl groups, C2-C24 heteroaryl groups, C3-C24 cycloalkyl groups, C5-C24 cycloalkenyl groups, C12-C24 cycloalkynyl groups, C3-C24 (cyclo)alkyl(hetero)aryl groups, C3-C24 (hetero)aryl(cyclo)alkyl, C4-C24 (cyclo)alkenyl(hetero)aryl groups, C4-C24 (hetero)aryl(cyclo)alkenyl groups, C4-C24 (cyclo)alkynyl(hetero)aryl groups, C4-C24 (hetero)aryl(cyclo)alkynyl groups, C4-C24 alkylcycloalkyl groups, and C4-C24 cycloalkylalkyl groups; wherein i is an integer in a range of from 0 to 4;
the R37 groups not being hydrogen are optionally substituted with a moiety selected from the group consisting of —Cl, —F, —Br, —I, —OH, —NH2, —SO3H, —PO3H, —PO4H2, —NO2, —CF3, ═O, ═NH, and —SH, and optionally contain one or more heteroatoms selected from the group consisting of O, S, NH, P, and Si, wherein the N, S, and P atoms are optionally oxidized, wherein the N atoms are optionally quaternized.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the radionuclide is selected from the group consisting of 3H, 11C, 13N, 150 18F, 19F, 51Cr, 52Fe, 52Mn, 55Co, 60Cu, 61Cu, 62Zn, 62Cu, 63Zn, 64Cu, 66Ga 67Ga, 68Ga 70As, 71As, 72As, 74As, 75Se, 75Br, 76Br, 77Br, 80Br, 82Br, 82Rb, 86Y, 88Y, 90Y, 89Sr, 89Zr, 97Ru, 99mTc, 110In, 111In, 113In, 114In, 117Sn, 120I, 122Xe, 123I, 124I, 125I, 166Ho, 167Tm, 169Yb, 193Pt, 195Pt, 201Tl, 203Pb, 24Na, 32P, 33P, 47Sc, 59Fe, 67Cu, 76As, 77As, 90Nb 03Ru, 105Rh, 109Pd, 111Ag, 111In, 121Sn, 127Te, 131I, 140La, 141Ce, 142Pr, 143Pr, 144Pr, 149Pm, 149Tb, 151Pm, 153Sm, 159Gd, 161Tb 165Dy, 166Dy, 169Er, 172Tm, 175Yb, 177Lu, 186Re, 188Re, 198Au, 199Au, 211At, 211Bi, 212Bi, 212Pb, 213Bi, 214Bi, 223Ra, 224Ra, 225Ac and 227Th.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the Label comprises a chelating moiety that chelates the radionuclide.

### Claim 18 (depends on 15)

The method according to claim 15, wherein X1, X2, X3, and X4 are —C(R47)2.

### Claim 19 (depends on 15)

The method according to claim 15, wherein the diene is a tetrazine satisfying Formula (4), and pharmaceutically accepted salts thereof:
wherein
each moiety Q1 and Q2 is independently selected from the group consisting of hydrogen, —F, —Cl, —Br, —I, —OR37, —N(R37)2, —SO3, —PO3—, —NO2, —CF3, —SR37, S(═O)2N(R37)2, OC(═O)R37, SC(═O) R37, OC(═S)R37, SC(═S)R37, NR37C(═O)—R37, NR37C(═S)—R37, NR37C(═O)O—R37, NR37C(═S)O—R37, NR37C(═O)S—R37, NR37C(═S)S—R37, OC(═O)N(R37)2, SC(═O)N(R37)2, OC(═S)N(R37)2, SC(═S)N(R37)2, NR37C(═O)N(R37)2, NR37C(═S)N(R37)2, C(═O)R37, C(═S)R37, C(═O)N(R37)2, C(═S)N(R37)2, C(═O)O—R37, C(═O)S—R37, C(═S)O—R37, C(═S)S—R37, S(O)R37, —S(O)2R37, NR37S(O)2R37, —ON(R37)2, —NR37OR37, alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, cycloalkyl groups, cycloalkenyl groups, cycloalkynyl groups, (cyclo)alkyl(hetero)aryl groups, (hetero)aryl(cyclo)alkyl, (cyclo)alkenyl(hetero)aryl groups, (hetero)aryl(cyclo)alkenyl groups, (cyclo)alkynyl(hetero)aryl groups, (hetero)aryl(cyclo)alkynyl groups, alkylcycloalkyl groups, and cycloalkylalkyl groups;
wherein the Q1 and Q2 groups not being H, —F, —Cl, —Br, —I, —OH, —NH2, —SO3, —PO3—, —NO2, —CF3, are optionally substituted with a moiety selected from the group consisting of —Cl, —F, —Br, —I, —OR37, —N(R37)2, —SO3R37, —PO3(R37)2, —PO4(R37)2, —NO2, —CF3, ═O, ═NR37, and —SR37, and optionally contain one or more heteroatoms selected from the group consisting of O, S, NR37, P, and Si, wherein the N, S, and P atoms are optionally oxidized, wherein the N atoms are optionally quaternized,
wherein the Q1 and Q2 groups are optionally bound to a polymer, a particle, a peptide, a peptoid, a dendrimer, a protein, an aptamer, a carbohydrate, an oligonucleotide, an oligosaccharide, a lipid, a steroid, a liposome, a Targeting Agent TT, —(SP)D—R87, an albumin-binding moiety, and a chelating moiety;
wherein D is 0 or 1;
SP is a spacer;
each R87 is independently selected from the group consisting of organic molecules, inorganic molecules, organometallic molecules, resins, beads, glass, microparticles, nanoparticles, gels, surfaces, and cells;
and at least one of moieties Q1 and Q2 is not hydrogen.

### Claim 20 (depends on 15)

The method according to claim 15, wherein X5 is —C(R47)2—.

### Claim 21 (depends on 15)

The method according to claim 15, wherein R48 is -LB.

### Claim 22 (depends on 15)

The method according to claim 15, wherein e is 0.

### Claim 23 (depends on 15)

The method according to claim 15, wherein each s is 0.

### Claim 24 (depends on 15)

The method according to claim 15, wherein i in Formula (3) is 0.

### Claim 25 (depends on 15)

The method according to claim 15, wherein i in Formula (3) is 1.

### Claim 26 (depends on 15)

The method according to claim 15, wherein Formula (1) comprises at most one CC.

### Claim 27 (depends on 15)

The method according to claim 15, wherein the time interval between the administration of the compound of Formula (1) and the diene is between 1 and 168 hours.

### Claim 28 (depends on 15)

The method according to claim 15, wherein the subject is a human.
